Dapagliflozin for the treatment of type 2 diabetes

被引：16

作者：

Abdul-Ghani, Muhammad A. ^{[1
]}

DeFronzo, Ralph A. ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2013年 / 14卷 / 12期

关键词：

dapagliflozin; kidney; SGLT2; inhibition; sodium-glucose cotransport; type; 2; diabetes; INADEQUATE GLYCEMIC CONTROL; RENAL GLUCOSE REABSORPTION; SELECTIVE SGLT2 INHIBITOR; DOUBLE-BLIND; BODY-WEIGHT; MELLITUS; METFORMIN; INSULIN; PHARMACOKINETICS; PIOGLITAZONE;

D O I：

10.1517/14656566.2013.812632

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. Areas covered: The aim of the present article is to review the efficacy and safety of dapagliflozin, a novel antihyperglycemic drug that lowers the plasma glucose concentration by the inhibition of renal sodium-glucose cotransport, in lowering the plasma glucose concentration and the HbA1c in T2DM patents. This review summarizes the published data about the mechanism of action and clinical efficacy of dapagliflozin in lowering the HbA1c in patients with T2DM. It also discusses additional non-glycemic benefits of dapagliflozin and the safety profile of the drug. Expert opinion: Dapagliflozin is effective in lowering the plasma glucose concentration in patients with T2DM with a good safety profile. Because of its unique mechanism of action, dapagliflozin can be utilized in combination with all other antihyperglycemic agents and at all stages of the disease.

引用

页码：1695 / 1703

页数：9

共 45 条

[11] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Pieters, Anne ;

Bastien, Arnaud ;

List, James F. .

LANCET, 2010, 375 (9733) :2223-2233

[12] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

[13] National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants [J].

Danaei, Goodarz ;

Finucane, Mariel M. ;

Lu, Yuan ;

Singh, Gitanjali M. ;

Cowan, Melanie J. ;

Paciorek, Christopher J. ;

Lin, John K. ;

Farzadfar, Farshad ;

Khang, Young-Ho ;

Stevens, Gretchen A. ;

Rao, Mayuree ;

Ali, Mohammed K. ;

Riley, Leanne M. ;

Robinson, Carolyn A. ;

Ezzati, Majid .

LANCET, 2011, 378 (9785) :31-40

[14]

DeFronzo RA, 2012, DIABETOLOGIA, V55, pS306

[15] From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].

DeFronzo, Ralph A. .

DIABETES, 2009, 58 (04) :773-795

[16] MOLECULAR ADAPTATIONS OF GLUT1 AND GLUT2 IN RENAL PROXIMAL TUBULES OF DIABETIC RATS [J].

DOMINGUEZ, JH ;

CAMP, K ;

MAIANU, L ;

FEISTER, H ;

GARVEY, WT .

AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (02) :F283-F290

[17] EFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE [J].

FARBER, SJ ;

BERGER, EY ;

EARLE, DP .

JOURNAL OF CLINICAL INVESTIGATION, 1951, 30 (02) :125-129

[18] Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial [J].

Ferrannini, Ele ;

Jimenez Ramos, Silvia ;

Salsali, Afshin ;

Tang, Weihua ;

List, James F. .

DIABETES CARE, 2010, 33 (10) :2217-2224

[19] Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial [J].

Henry, R. R. ;

Murray, A. V. ;

Marmolejo, M. H. ;

Hennicken, D. ;

Ptaszynska, A. ;

List, J. F. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (05) :446-456

[20] Is glycemic control improving in US adults? [J].

Hoerger, Thomas J. ;

Gregg, Edward W. ;

Segel, Joel E. ;

Saaddine, Jinan B. .

DIABETES CARE, 2008, 31 (01) :81-86

← 1 2 3 4 5 →